VIVS

VivoSim Labs, Inc.
CAPPED RATING

VivoSim Labs, Inc. (VIVS) is rated D+ (1.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (F). The rating has held at D+ for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.5 / 5.0
D+
Value
B-
Factor Score 2.9 / 5.0
Growth
F
Factor Score 0.7 / 5.0
Profitability
D-
Factor Score 0.9 / 5.0
Momentum
F
Factor Score 0.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA -0.1
Rev Growth YoY -51.4%
Gross Margin 0.0%
Price Return 3M -59.4%
Price Return 12M -94.3%
Catalyst Signal 0.00
Market Cap $2.6M
TTM Revenue $112.0K
Price / Sales 23.0
ROE -343.1%

Historical Factor Score Progression

Held D+ for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B- (2.9) F (0.7) D- (0.9) F (0.6) C+ (2.6) D+ (1.5)
2026-11-08 B- (2.9) F (0.6) D- (0.8) F (0.6) C+ (2.6) D+ (1.5)
2026-11-01 B- (2.9) F (0.6) D- (0.9) F (0.7) C+ (2.7) D+ (1.5)
2026-10-25 B- (2.9) F (0.6) D- (0.8) F (0.5) C+ (2.6) D (1.5)
2026-10-18 B- (2.9) F (0.6) D- (0.8) F (0.5) C+ (2.6) D (1.5)
Page 1 of 4